United States · Platforms & data · Benzinga
AstraZeneca Secures Dual Rare Disease and Bladder Cancer Approvals Across US, Europe

Detailed summary
Regulators in the U.S. and European Union handed AstraZeneca Plc (NYSE:AZN) major regulatory wins across rare neuromuscular disease and oncology. The agencies cleared Klygefa for…
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.benzinga.com)



